Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2023/2024
The following technology appraisals have been endorsed during 2022/23. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2024
TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
February 2024
Note this guidance updates and replaces NICE Technology Appraisal TA693, endorsed by the DoH in May 2021.
TA943 - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
January 2024
TA942 - Empagliflozin for treating chronic kidney disease
TA937 - Targeted-release budesonide for treating primary IgA nephropathy
December 2023
TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer ‘Note this guidance updates and replaces NICE Technology Appraisal TA885, endorsed by the DoH in May 2023.’
TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa
TA934 - Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia
TA926 - Baricitinib for treating severe alopecia areata
TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis
TA924 - Tirzepatide for treating type 2 diabetes
TA922 - Daridorexant for treating long-term insomnia
TA921 - Ruxolitinib for treating polycythaemia vera
TA920 - Tofacitinib for treating active ankylosing spondylitis
TA919 - Rimegepant for treating migraine
TA918 - Bimekizumab for treating axial spondyloarthritis
TA916 - Bimekizumab for treating active psoriatic arthritis
TA915 - Pegunigalsidase alfa for treating Fabry disease
November 2023
TA913 - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
TA912 - Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
August 2023
TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
TA909 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
‘Note this guidance updates and replaces NICE Technology Appraisal TA620, endorsed by the DoH in February 2020.’
TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis
TA906 - Rimegepant for preventing migraine
July 2023
TA905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease
TA900 - Tixagevimab plus cilgavimab for preventing COVID-19
June 2023
TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
‘Note this guidance updates and replaces NICE Technology Appraisal TA573, endorsed by the DoH in May 2019.’
TA896 - Bulevirtide for treating chronic hepatitis D
TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma
TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma
TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
TA890 - Difelikefalin for treating pruritus in people having haemodialysis
TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease
‘Note this guidance updates and replaces NICE Technology Appraisal TA831, endorsed by the DoH in October 2022.’
May 2023
TA885 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer ‘Note this guidance has been updated and replaced by TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer, endorsed by the DoH in December 2023.’
TA882 - Voclosporin with mycophenolate mofetil for treating lupus nephritis
TA881 - Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
TA880 - Tezepelumab for treating severe asthma
April 2023
TA877 - Finerenone for treating chronic kidney disease in type 2 diabetes
TA875 - Semaglutide for managing overweight and obesity